Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Outsourcing-pharma17h
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Zacks Small Cap Research on MSN17h
LEXX: IRB Approval Clears Way for GLP-1 Study #5
LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
News Medical on MSN16h
GLP-1RA initiation linked to new thyroid cancer diagnoses
Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...
Labroots8h
Exploring the Effects of GLP-1 Receptor Agonists Across the Body
Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...
rheumatologyadvisor17h
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.
The Lancet8h
Weight-loss medications: promoting health and not harm
In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...
emjreviews.com22h
GLP-1 Receptor Agonists Linked to Behavioural Side Effects
A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...